A long-term treatment for AD

Dupilumab offers safe, long-term option for atopic dermatitis

A recent study reports findings that support dupilumab as a safe, long-term treatment in patients with moderate-to-severe atopic dermatitis.

Skin microbiome as clinical biomarker for atopic dermatitis

With advancements in deep next-generation sequencing (NGS) and bioinformatics analysis, the authors of a recent study suggest the skin microbiome may hold promise as a clinical biomarker in atopic dermatitis (AD) management.